GSTA4的双重隔室化机制可抑制铁死亡,促进前列腺癌对抗雄激素治疗的耐药性
Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer
Yong Luo, Wei Zhuang, Zean Li, Yiming Lai, Yongyi Ou, Dongquan Li, Shanhe Huang, Tianlong Luo, Jintao Hu, Bingliang Chen, Jianhan Fu, Tao Zhuo, Hankun Jiang, Yin Lu, Hai Huang, Kewei Xu, Shengmeng Pe
Journal:Advanced Science
IF:14.1
DOI:10.1002/advs.77908
PMID:42801628
Published:2026-09-27
research field:分子生物学植物化学氧化应激免疫学炎症呼吸医学民族药理学
Abstract
Resistance to second-generation antiandrogens poses a major therapeutic challenge in castration-resistant prostate cancer (CRPC). While ferroptosis evasion has been implicated in treatment failure, the key molecular determinants driving this evasive process are poorly understood. Using integrated multi-omics analyses of resistant models and patient specimens, we identify glutathione S-transferase alpha 4 (GSTA4) as a pivotal ferroptosis suppressor that is associated with adverse clinical outcomes and drives antiandrogen resistance via a dual compartmentalization mechanism. Our data demonstrate that GSTA4 not only detoxifies the lipid peroxidation product 4-hydroxynonenal in the cytosol but also translocates to the mitochondria under ferroptotic stress. GSTA4 interacts with PGAM5 to prevent the dephosphorylation of Drp1 at Ser637, thereby maintaining mitochondrial fitness and suppressing ferroptosis. This spatially coordinated defense program is crucial for antiandrogen resistance, as GSTA4 knockdown sensitizes tumors to antiandrogen therapy. Virtual screening and surface plasmon resonance assays identify metformin as a candidate GSTA4 inhibitor. Targeting GSTA4 with metformin restores ferroptosis sensitivity and reverses antiandrogen resistance both in vitro and in vivo. Our findings uncover a spatially coordinated anti-ferroptotic mechanism underlying antiandrogen resistance and highlight targeting GSTA4 as a promising combination strategy for CRPC treatment.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


